Spectral AI, Inc. (MDAI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several negative factors: reduced revenue guidance, increased dependence on the BARDA contract, rising operating costs, and a net loss increase. Although there are some positive aspects, such as FDA submission progress and positive feedback from international markets, these are overshadowed by the negative financial trends and uncertainties about future revenue and commercialization. The Q&A session further underscores these concerns, with management providing vague responses on critical matters, contributing to a negative sentiment and likely negative stock price reaction.
Key Financial Performance
Cash Balance $10.5 million, remained flat from the second quarter of 2025. This was due to stock option and warrant exercises and efficient operating expense management. Additionally, a registered direct offering in October added $7.6 million to cash reserves.
Research and Development Revenue $3.8 million, decreased from $8.2 million in Q3 2024. The reduction was due to anticipated lower reimbursements under the BARDA Project BioShield contract and reduced direct labor and clinical trial costs after the FDA de novo submission.
Gross Margin 42.7%, decreased from 44.8% in Q3 2024. The decline was attributed to a lower percentage of direct labor as part of total reimbursed costs under the BARDA Project BioShield contract.
General and Administrative Expenses $5 million, increased from $4.6 million in Q3 2024. The rise was due to higher third-party adviser and consulting costs and an increase in non-billable work unrelated to the BARDA Project BioShield contract.
Net Loss $3.6 million, increased from $1.5 million in Q3 2024. The increase was due to reduced research and development revenue and higher general and administrative expenses.
Shares Outstanding 27,251,034 shares as of September 2025.
Cash and Cash Equivalents $10.5 million as of September 30, 2025, up from $5.2 million on December 31, 2024. The increase was due to stock option and warrant exercises and efficient expense management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DeepView system: The company is preparing for the U.S. launch of the DeepView system next year. The system has broad applications, including burns, and has received support from the burn and wound community. The company is also refining its commercialization strategy.
Market expansion: The company is focusing on the U.S. market for the DeepView system and has not yet included sales contributions from the United Kingdom or Australia in its revenue guidance.
Cash reserves: Cash reserves increased to $10.5 million as of September 30, 2025, up from $5.2 million at the end of 2024. This includes proceeds from stock option exercises and a $7.6 million direct offering in October 2025.
Revenue guidance: Revenue guidance for 2025 was reduced from $21.5 million to $18.5 million due to reduced work on the BARDA Project BioShield contract and timing effects from the U.S. government shutdown.
Net loss: The company reported a net loss of $3.6 million for Q3 2025, compared to $1.5 million in Q3 2024, due to reduced R&D revenue and higher administrative expenses.
FDA submission: The FDA submission for the DeepView system was completed in June 2025. The company is actively engaging with the FDA on the de novo application despite delays caused by the U.S. government shutdown.
Commercialization strategy: The company is working with BARDA partners to bring the DeepView system to market and is refining its commercialization strategy for a planned release next year.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
FDA Submission Delays: The U.S. government shutdown has slowed interactions with the FDA on the de novo application, potentially delaying the approval process for the DeepView system.
Reduced R&D Revenue: Research and development revenue decreased significantly from $8.2 million in Q3 2024 to $3.8 million in Q3 2025, reflecting reduced reimbursements under the BARDA Project BioShield contract.
Increased Net Loss: The company reported a net loss of $3.6 million in Q3 2025, up from $1.5 million in Q3 2024, due to reduced R&D revenue and higher general and administrative expenses.
Lower Gross Margin: Gross margin decreased to 42.7% in Q3 2025 from 44.8% in Q3 2024, driven by a lower percentage of direct labor as a portion of reimbursed costs under the BARDA contract.
Revenue Guidance Reduction: Revenue guidance for 2025 was reduced from $21.5 million to $18.5 million, attributed to reduced work on the BARDA contract and timing effects from the U.S. government shutdown.
Dependence on BARDA Contract: The company's financial performance is heavily reliant on the BARDA Project BioShield contract, which has seen reduced activity and reimbursements.
Increased Operating Costs: General and administrative expenses rose to $5 million in Q3 2025 from $4.6 million in Q3 2024, driven by higher third-party adviser and consulting costs and non-billable work.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has reduced its revenue guidance for 2025 from $21.5 million to $18.5 million. This reduction is attributed to anticipated reduced work on the BARDA Project BioShield contract following the FDA submission and timing effects from the U.S. government shutdown. The company expects to recover these effects largely within the first half of 2026. The guidance does not include potential sales of the DeepView system for burn indications in the United Kingdom or Australia.
Product Commercialization: The company plans to launch the DeepView system in the U.S. next year, with ongoing preparations for its commercialization strategy. The system is expected to have broad applications beyond burns, supported by the burn and wound care community.
FDA Submission and Approval: The FDA submission for the DeepView system was completed in June 2025. The company is actively engaging with the FDA on the de novo application process, despite some delays caused by the U.S. government shutdown.
Financial Position: The company has over $10 million in cash reserves as of September 2025, with an additional $7.6 million raised through a registered direct offering in October 2025. This funding is deemed sufficient to support operations and product commercialization efforts for the foreseeable future.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the impact of the government shutdown on the FDA submission and BARDA contract?
A:The government shutdown caused some delays in conversations with BARDA and the development of the DeepView system. However, the FDA submission is still on track for the first half of 2026, and the BARDA contract remains active through the first quarter of 2026.
Q:What is the revenue outlook for 2026?
A:2026 is expected to be a down year in revenue compared to 2024 and 2025, with relatively flat or slightly lower revenue compared to 2025. Significant growth is anticipated in 2027 and 2028 as the device is commercialized.
Q:What feedback has been received from international markets regarding the device?
A:Feedback from international markets has been overwhelmingly positive, highlighting ease of use and helpfulness. This feedback has informed minor adjustments in the next iteration of the Phoenix device.
Q:How are communications with the FDA progressing?
A:Communications with the FDA have been frequent and positive. The statistical analysis plan (SAP) for the AI algorithm has been well-received. Additional human factors studies and reliability testing are being discussed, and further clarity is expected in upcoming calls.
Q:What is the status of the handheld module development?
A:The handheld module, primarily a military project, is progressing well with positive feedback on its design. It is undergoing testing for military environments, and discussions are ongoing for a civilian version. The cart-based device will remain the primary focus for now.
Q:What are the commercialization preparation activities?
A:A commercialization team is in place, with plans to hire four more FTEs in 2026. The BARDA budget supports initial commercialization costs. The burn community is familiar with the technology, and the BARDA contract includes clauses for device placement in burn centers.
Q:How were the presentations at the European Burn Association received?
A:The presentations were well-received, with strong interest in the technology. Plans are in place to expand into the European market, including obtaining UKCA and CE Mark clearances.
Q:What is the status of the Spectral IP transaction?
A:The Spectral IP transaction is under SEC review and is expected to close in the first quarter of 2026, with financial impacts reflected in that quarter.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the additional requests or outstanding items from the FDA, citing confidentiality. They also did not provide detailed timelines or specifics on the civilian version of the handheld module or the exact commercialization strategy beyond general plans.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI Finance
AI chairman
CPT code
Counsel maam
DeepView system
Dr
FDA de
Finance Focus
Focus finish
Investors afternoon
Number finish
Number focus
Sara afternoon
abstract forum
addition support
application development
application indication
application speed
balance efficiency
burn CPT
burn community
burn conference
calendar FDA
call mantra
cash balance
cash reserve
chairman Sara
de novo
hand
marketplace
novo application
offering
publication
stock
support burn
MDAI Transcript
Spectral AI, Inc. (MDAI) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings report shows strong financial performance with significant revenue and net income growth, improved gross margin, and positive cash flow. Despite increased operating expenses, the focus on R&D suggests future growth potential. However, the lack of discussion on strategic initiatives and operational updates, along with the acknowledgment of risks in forward-looking statements, tempers the outlook slightly. Overall, the financial performance suggests a positive sentiment, likely resulting in a stock price increase of 2% to 8% over the next two weeks.
Spectral AI, Inc. (MDAI) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call summary shows mixed signals: improved net income and cash position are positive, but declining gross margins and R&D revenue are concerns. The Q&A section highlights strategic planning for commercialization but lacks specific details, which raises uncertainty. The absence of guidance adjustments and unclear management responses further contribute to a neutral sentiment. Overall, while there are positive elements, the uncertainties and lack of immediate catalysts keep the stock reaction neutral.
Spectral AI, Inc. (MDAI) Q3 2025 Earnings Call Transcript
Unknown11-11
The earnings call highlights several negative factors: reduced revenue guidance, increased dependence on the BARDA contract, rising operating costs, and a net loss increase. Although there are some positive aspects, such as FDA submission progress and positive feedback from international markets, these are overshadowed by the negative financial trends and uncertainties about future revenue and commercialization. The Q&A session further underscores these concerns, with management providing vague responses on critical matters, contributing to a negative sentiment and likely negative stock price reaction.
Spectral AI, Inc. (MDAI) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call reveals several concerning factors: a decreased gross margin, increased net loss, and heavy reliance on FDA approval and BARDA contract. The Q&A section indicates management's uncertainty regarding commercialization timelines and reliance on government contracts. Despite a reduction in G&A expenses, the financial strain from a significant net loss and limited revenue diversification suggests a negative outlook. The lack of immediate sales in international markets further compounds these issues. Consequently, the predicted stock price movement over the next two weeks is negative (-2% to -8%).
MDAI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
